Skip to main navigation

Investors
News
- News Releases
- News and Mentions
Presentations & Events
- Presentations
- Events
Stock Performance
- Stock Information
- Analyst Coverage
Financials & Filings
- SEC Filings
- Quarterly Results
Corporate Governance
Resources

News Releases

Year

Mar 08 / 23

Belite Bio announces submission of Clinical Trial Application for Phase 3 Stargardt Disease study of Tinlarebant (LBS-008) in South Korea

Jan 31 / 23

Belite Bio Submits IND Amendment to Initiate Phase 3 Clinical Trial of Tinlarebant (LBS-008) in Advanced Dry AMD

Jan 11 / 23

Belite Bio Receives Approval to Initiate Tinlarebant (LBS-008) Phase 3 Clinical Trial for Stargardt Disease in the Netherlands

Jan 05 / 23

Belite Bio announces submission of Clinical Trial Application for Netherlands Phase 3 study of Tinlarebant (LBS-008)

Belite Bio™ Inc
5820 Oberlin Drive, Suite 101,
San Diego CA, 92121 USA

Join our mailing list.

Sign up to receive important updates and news from Belite Bio